Bai Hua, Chen Guojing, Fang Congwen, Yang Xuekang, Yu Sixun, Hai Chunxu
Department of Toxicology, Shaanxi Provincial Key Lab of Free Radical Biology and Medicine, the Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China.
Department of Orthopedics, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
J Clin Transl Res. 2015 Dec 12;1(3):168-179. eCollection 2015 Dec 30.
Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. OS is associated with locally aggressive growth and high metastatic potential. The mechanisms that underlie these processes are currently elusive. Reactive oxygen species (ROS) and Na/H exchanger 1 (NHE1) have been suggested to regulate proliferation and migration of tumor cells. However, the relationship between NHE1 and ROS in OS proliferation and migration has not been investigated before.
To investigate the role of NHE1 and ROS in the proliferation and migration of OS.
ROS levels and NHE1 expression were studied in cultured human OS cells and human OS xenografts in nude mice. In vitro, OS cells were treated with different doses of tert-butyl hydroperoxide (tBHP), a ROS inducer, and cariporide, an NHE1 inhibitor, to study the effect on cell proliferation and migration. In vivo, nude mice bearing OS cells were administrated with NHE1 inhibitor or antioxidant and the tumor weights were measured.
This study reported for the first time that the expression of NHE1 and intracellular ROS level were both increased in OS tissues and cells. Exposure of OS cell to ROS derived from tBHP was able to accelerate cell proliferation and migration and also up-regulate NHE1 protein expression. Moreover, tBHP significantly increased intracellular pH (pHi), decreased extracellular pH (pHe) and induced upregulation of ERK, MMP2, and MMP9. Lowering of ROS levels with the anti-oxidant DMTU or inhibiting NHE1 activity via cariporide abolished the stimulatory effect of tBHP. However, there cariporide did not affect intracellular ROS levels. In vivo study we further confirmed that cariporide could inhibit tumor growth in the nude mouse xenografts of OS cells.
The data demonstrate that up-regulation of NHE1 was induced by low concentrations of ROS contributes to the regulation of tumor proliferation and invasion of OS.
There is potential application for cariporide as an effective antitumor agent during the development of human osteosarcoma. In addition, redox modulation on proton transport may represent a novel target of osteosarcoma prevention, and open a new avenues for future research.
骨肉瘤(OS)是儿童和青少年中最常见的原发性恶性骨肿瘤。骨肉瘤与局部侵袭性生长和高转移潜能相关。这些过程背后的机制目前尚不清楚。活性氧(ROS)和钠/氢交换体1(NHE1)已被认为可调节肿瘤细胞的增殖和迁移。然而,NHE1与ROS在骨肉瘤增殖和迁移中的关系此前尚未被研究。
研究NHE1和ROS在骨肉瘤增殖和迁移中的作用。
在培养的人骨肉瘤细胞和裸鼠体内的人骨肉瘤异种移植模型中研究ROS水平和NHE1表达。在体外,用不同剂量的ROS诱导剂叔丁基过氧化氢(tBHP)和NHE1抑制剂卡立泊来德处理骨肉瘤细胞,以研究对细胞增殖和迁移的影响。在体内,给荷骨肉瘤细胞的裸鼠施用NHE1抑制剂或抗氧化剂,并测量肿瘤重量。
本研究首次报道NHE1的表达和细胞内ROS水平在骨肉瘤组织和细胞中均升高。将骨肉瘤细胞暴露于tBHP产生的ROS中能够加速细胞增殖和迁移,并上调NHE1蛋白表达。此外,tBHP显著升高细胞内pH(pHi),降低细胞外pH(pHe),并诱导ERK、MMP2和MMP9的上调。用抗氧化剂二甲基硫脲降低ROS水平或通过卡立泊来德抑制NHE1活性可消除tBHP的刺激作用。然而,卡立泊来德不影响细胞内ROS水平。体内研究进一步证实卡立泊来德可抑制骨肉瘤细胞裸鼠异种移植模型中的肿瘤生长。
数据表明低浓度ROS诱导的NHE1上调有助于调节骨肉瘤的肿瘤增殖和侵袭。
卡立泊来德作为一种有效的抗肿瘤药物在人类骨肉瘤的治疗中具有潜在应用价值。此外,对质子转运的氧化还原调节可能代表骨肉瘤预防的一个新靶点,并为未来的研究开辟新途径。